Abstract

COVID-19 and dengue disease are challenging to tell apart because they have similarities in clinical and laboratory features during the acute phase of infection, leading to misdiagnosis and delayed treatment. The present study evaluated peripheral blood cell count accuracy to distinguish COVID-19 non-critical patients from non-severe dengue cases between the second and eleventh day after symptom onset. A total of 288 patients infected with SARS-CoV-2 (n = 105) or dengue virus (n = 183) were included in this study. Neutrophil, platelet, and lymphocyte counts were used to calculate the neutrophil–lymphocyte ratio (NLR), the platelet–lymphocyte ratio (PLR), and the neutrophil–lymphocyte*platelet ratio (NLPR). The logistic regression and ROC curves analysis revealed that neutrophil and platelet counts, NLR, LPR, and NLPR were higher in COVID-19 than dengue. The multivariate predictive model showed that the neutrophils, platelets, and NLPR were independently associated with COVID-19 with a good fit predictive value (p = 0.1041). The neutrophil (AUC = 0.95, 95% CI = 0.84–0.91), platelet (AUC = 0.89, 95% CI = 0.85–0.93) counts, and NLR (AUC = 0.88, 95% CI = 0.84–0.91) were able to discriminate COVID-19 from dengue with high sensitivity and specificity values (above 80%). Finally, based on predicted probabilities on combining neutrophils and platelets with NLR or NLPR, the adjusted AUC was 0.97 (95% CI = 0.94–0.98) to differentiate COVID-19 from dengue during the acute phase of infection with outstanding accuracy. These findings might suggest that the neutrophil, platelet counts, and NLR or NLPR provide a quick and cost-effective way to distinguish between dengue and COVID-19 in the context of co-epidemics in low-income tropical regions.

Highlights

  • Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a public health emergency affecting more than 200 countries worldwide [1]

  • According to the reported clinical data, fever was found to be a manifestation reported with a high frequency and headache in more than 70% of the cases of both COVID-19 and dengue during acute infection (Table 1)

  • Lower respiratory symptoms could help distinguish between patients infected with SARS-CoV-2 and Dengue virus (DENV)

Read more

Summary

Introduction

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a public health emergency affecting more than 200 countries worldwide [1]. The COVID-19 pandemic continues to spread worldwide, including subtropical and tropical regions where endemic diseases, such as dengue, are part of continuing public health surveillance [3,4,5]. Dengue virus (DENV) is the etiological agent of dengue disease classified into non-severe and severe dengue, with fatal complications in the severe cases [3]. Patients with dengue or COVID-19 develop symptoms (within 4 to 10 days; incubation period), including fever, headache, rash, myalgia, arthralgia, diarrhea, nausea, and vomiting [6,7,8]. The patients from dengue-endemic regions with confirmed cases of COVID-19 must be explored for both diseases

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call